SPLITOAK STRATEGIES LLC

Lobbying for ALKERMES, INC. · Global biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Medicare/Medicaid

Advance the use and funding of FDA-approved medicines to treat serious mental illness; protecting patient access to mental health medications in public programs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.